PTM Therapeutics was founded in 2020 based on the realization that post-translational modifications create highly specific disease targets for therapeutic antibodies. Our oncology program utilizes an antibody-drug conjugate (ADC) approach to treating metastatic colon cancer. We are targeting a glycan target that is upregulated on primary colon cancers and colon cancer metastases. We have xenograft data showing efficacy and safety. We also pursuing a second program for the treatment of colitis including radiation-induced colitis. We are currently raising a seed round to support crucial research to enable IND enabling activities.